AUAndrey Yu. Ustyugov

Andrey Yu. Ustyugov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrey Yu. Ustyugov has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prospects for using orthobiologic products in knee osteoarthritis: а review

    by Andrey Yu. Ustyugov, Alexander N. Torgashin, Alla I. Zorina, Vadim L. Zorin, Pavel B. Kopnin, Устюгов Андрей Юрьевич

    Osteoarthritis is the most common joint disease, causing damage to cartilage and surrounding tissues and potentially leading to varying degrees of disability. The disease is characterized by pain, stiffness, and loss of function. Osteoarthritis is classified as primary and secondary. The cause of primary (or idiopathic) osteoarthritis is unknown (primary osteoarthritis accounts for the vast majority of cases). Secondary osteoarthritis may be caused by another disease or disorder, such as infection, congenital joint malformation, trauma, metabolic disorders, rheumatoid arthritis, and others. The main goals of treatment include relief of pain, preservation of joint flexibility, and optimization of joint function. Currently used conservative treatment methods are mainly aimed at reducing pain and improving the patient’s quality of life; however, they do not eliminate the underlying cause of the disease and, accordingly, are not capable of completely halting the degradation of hyaline cartilage. Attempts at joint-preserving surgery in cases of involvement of one of the knee joint compartments, such as corrective osteotomy, can significantly improve treatment outcomes but tend to delay rather than prevent the need for joint arthroplasty. Therefore, the development of treatment methods that enable joint preservation and restoration of cartilage and subchondral bone defects remains highly relevant. At present, the search for such methods is focused on the use of orthobiologic products. This article addresses the application of these approaches in the treatment of knee joint conditions. A detailed description of the composition and mechanisms of action of two orthobiologic products of greatest interest to practicing clinicians—platelet-rich plasma and stromal vascular fraction—is presented. The results of preclinical and clinical studies demonstrating the ability of these products to reduce inflammation, alleviate pain, and remarkably improve the function of the affected joint are provided. Thus, scientific studies confirm the therapeutic efficacy of orthobiologic products, the use of which opens new prospects for joint-preserving treatment of patients with osteoarthritis.

  • Current status of biomedical products for gene and cell therapy of recessive dystrophic epidermolysis bullosa (review, part IV)

    by A.I. Zorina, V.L. Zorin, P.B. Kopnin, A.A. Isaev, N.E. Manturova, R.T. Abdullaev, A.YU. Ustyugov

    Recessive dystrophic epidermolysis bullosa (RDEB) is one of the main types of epidermolysis bullosa, a rare, severe, genetic disease characterized by systemic chronic inflammation, blisters, erosions and extensive chronic wounds on the skin and a tendency to squamous cell carcinoma development. The disease is caused by pathogenic variant of COL7A1 gene encoding the synthesis of type VII collagen (C7), that is the main component of the anchorage fibrils, which maintain the adhesion between the epidermis and the underlying dermis. The disease is debilitating. Treatment methods mainly include supportive measures so the development of treatment methods that directly affect the cause of the disease is very relevant. The article is devoted to the possibility of using one of the most promising treatment strategies of RDEB — gene editing in patients with RDEB by means of specific nucleases, namely TALEN (Transcription activator-like effector nucleases) and CRISPR/Cas (Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-Associated protein) that allows to almost irreversibly restore the C7 synthesis. The method is at preclinical stage. The results of preclinical studies, comparative analysis of used methods, as well as approaches that may help to implement this method of RDEB gene therapy in clinical practice in the nearest future are presented.

  • Current status of biomedical products for gene and cellular therapy of recessive dystrophic epidermolysis bullosa (review, part III)

    by A.I. Zorina, V.L. Zorin, P.B. Kopnin, A.A. Isaev, N.E. Manturova, R.T. Abdullaev, A.YU. Ustyugov

    Recessive dystrophic epidermolysis bullosa is one of the most severe hereditary diseases molecular pathology of which is associated with biallelic mutation variants with loss of function in COL7A1 gene coding type VII collagen (C7). In this regard, one of the main approaches of RDEB gene therapy is the development of gene replacement therapy methods that involves substitution of a mutant gene allele to exogenous full-length wild type gene by transduction of the latter in the skin cells. The development is carried out in two directions — ex vivo to obtain transgenic skin equivalents (both mono- and bilayer) and in vivo — application of the gene product directly in the patient’s body. In particular, a gene product for topical use (Beremagene geperpavec, B-VEC) has been developed and already introduced into clinical practice, action of which is aimed at restoring C7 synthesis by both types of skin cells producing this protein. The article is devoted to methods of gene replacement therapy for treatment of patients with recessive dystrophic epidermolysis bullosa. The results of pre-clinical and clinical trials as well as developed gene products, vectors of their delivery to the skin, prospects for development of this area of gene therapy and challenges ahead are described in detail.

  • Current status of biomedical products for gene and cellular therapy of recessive dystrophic epidermolysis bullosa (review, part II)

    by A.I. Zorina, V.L. Zorin, P.B. Kopnin, A.A. Isaev, N.E. Manturova, R.T. Abdullaev, A.YU. Ustyugov

    Recessive dystrophic epidermolysis bullosa (RDEB) is a rare hereditary disease characterized by a high skin susceptibility, formation of bubbles, erosions, chronic lesions, chronic systemic inflammation. The use of mesenchymal stem/stromal cells (MSCs) isolated from different sources can be considered as one of the RDEB treatment methods. MSCs are an ideal candidate for treating a wide range of serious diseases due to the simplicity of their isolation and reproduction, the ability to differentiate into multiple cell lines, the ability to neovasculogenesis, as well as in consequence of the pronounced paracrine effect through the production of anti-inflammatory, immunomodulating, antiapoptotic, antifibrotic and anabolic factors, that leads to damaged tissues’ recovery. At the same time, MSCs have a low immunogenicity that allows to use allogenic MSCs (without the need for aggressive patient’s conditioning as in the case of allogenic transplantation of bone marrow cells), that is especially relevant due to the RDEB nature associated with systemic inflammation. This therapy can significantly decrease the disease activity and improve the life quality of patients with RDEB by reducing inflammatory processes in the body and relieving persistent and highly disturbing symptoms — itching and pain. The article summarizes the mechanisms by which MSCs contribute to healing skin lesions, systemic anti-inflammatory effect in the treatment of patients with RDEB. The results of pre-clinical and clinical studies have been also discussed.

  • Open Access

    Comparative analysis of pretarsal and sub-brow blepharoplasty for correction of age-related upper eyelid changes in Asian race patients

    by N. E. Manturova, V. I. Sharobaro, H. Le, T. S. Nguyen, D. B. Nguyen, M. V. Anurov, H. N. Nguyen, A. Yu. Ustyugov, А. Ю. Устюгов

    The purpose of a study was to compare the blepharoplasty methods of pretarsal (Asian eyelid blepharoplasty) and sub-brow approaches in patients of the Asian ethnic group based on the analysis the surgical correction results of age-related upper eyelids changes.Material and methods. The prospective clinical study included 133 mongoloid race people aged 45 to 71 years in the period up 2019 to 2024. The study participants were randomly divided into two groups. The 1st group (72 people) underwent age-related Asian blepharoplasty using a pretarsal approach, the 2nd group (61 people) underwent blepharoplasty using a sub-brow approach. The validated FACE-Q Satisfaction with Eyes questionnaire was used to assess the treatment results before, 3 and 6 months after blepharoplasty.Results. Comparison of preoperative groups with blepharoplasty did not reveal statistically significant differences in satisfaction with eye appearance (p = 0.089). After blepharoplasty, we were unable to find differences between the study groups when assessing the degree of satisfaction with the appearance of the eyes after 3 months (92 (92–100) in patients of the 1st group and 92 (92–100) in patients of the 2nd group, p = 0.192). The score 6 months after blepharoplasty was statistically significantly higher in patients of 2nd group than in study participants from 1st group 100 (92–100), 96 (92–100) points, respectively, p = 0.027).No complications such as postoperative brow ptosis or recurrence of lateral blepharochalasis were observed performing blepharoplasty using a sub-brow approach (group 2). This fact indicates that the risk of these complications is minimized.Conclusion. Blepharoplasty using a sub-brow approach is a promising method of surgical correction of agerelated upper eyelids changes in patients of the Asian ethnic group, showing comparable effectiveness in comparison with age-related blepharoplasty of Asian eyelids. Using myo-periosteal fixation, this technique gives fewer complications in the form of postoperative brow ptosis.

  • Current status of biomedical products for gene and cellular therapy of recessive dystrophic epidermolysis bullosa (part I)

    by A.I. Zorina, V.L. Zorin, P.B. Kopnin, A.A. Isaev, N.E. Manturova, R.T. Abdullaev, A.YU. Ustyugov

    A detailed review of current products and innovative strategies of gene and cellular therapy, which are at different study phases, in the treatment of recessive dystrophic epidermolysis bullosa (RDEB) is provided. The most promising in cellular RDEB therapy is application of allogenic mesenchymal stromal/stem cells that can be injected intradermally and intravenously. Genetically modified autologous dermal fibroblasts, which are injected intradermally along the wound edges also should be noted among the injection methods. Epidermal transplants, based on patient’s autologous keratinocytes, have been developed ex vivo on the basis of gene therapy methods. Products based on double-layer transplants, including both types of skin cells producing C7, have been developed as well. These are the most advanced technologies in pre-clinical and clinical studies, and the gene product in vivo, namely a local gene therapy on the basis of herpes simplex virus type 1 aimed at C7 protein restoration by delivering COL7A1, is the first method of gene therapy, that can already be used in a clinical setting for RDEB treatment. Products based on gene editing using nucleases are also being developed. The review discusses in detail the results of pre-clinical and clinical studies of above mentioned products.


  • Evaluation of blepharoplasty outcomes using psychometric scales

    by D.B. Nguyen, N.E. Manturova, V.I. Sharobaro, H.N. Nguyen, T.T. Hoang, A.YU. Ustyugov

    The eyes and periorbital area are central to perception of facial beauty and age. Aesthetic surgeries in this area can dramatically improve the appearance of men and women. Blepharoplasty is one of the most common aesthetic surgeries worldwide. Satisfaction with appearance and improved quality of life are important criteria for patients evaluating the results after eyelid surgery. PROM questionnaires are valuable for quantitative self-assessment of outcomes after blepharoplasty. The purpose of our study was to compare the main PROM scales for evaluating the results of blepharoplasty. We reviewed some PROMs, including Blepharoplasty Outcomes Evaluation (BOE), Glasgow Benefit Inventory (GBI) and FACE-Q. Studies revealed significant improvement in patient satisfaction after surgery, especially in appearance and psychoemotional state. Introduction of specialized scales, such as the FACE-Q Eye module, made it possible to assess satisfaction and quality of life of patients after blepharoplasty. Despite high satisfaction with postoperative outcomes, analysis of results and thorough assessment of the risk of complications are necessary to improve blepharoplasty techniques.


  • Skin aging associated with involutional changes in fibroblastic differon and extracellular matrix of the dermis

    by A.I. Zorina, V.L. Zorin, P.B. Kopnin, A.YU. Ustyugov, N.E. Manturova

    In aging, two types of fundamental molecular mechanisms in the skin are involved. One of them involves the main cell population of the dermis, fibroblasts, their number and functional activity; the other is associated with a homeostasis disorder of the extracellular matrix (ECM) of the dermis and its main structural component, collagen. With age, the population of dermal fibroblasts is decreasing, primarily due to the depletion of precursor cells, leading to a decrease in the regenerative potential of the skin tissue. At the same time, there are structural, quality, and functional disorders of the dermal ECM associated with its ultrastructural, morphometric, mechanical, and conformational changes, which entail a dysfunction of dermal fibroblasts. The latter contributes to the positive feedback that stimulates further ECM degradation. All these destructive processes form a vicious circle, leading to the constant progression of skin aging. This article describes the cellular and molecular mechanisms of these processes. Their study and understanding are significant since it opens the way for a competent solution and the search for new approaches to solving the extremely urgent skin aging problem.